Your resource for exploring the least burdensome path for bringing new
technologies to market What is the Interagency
Council?
Why should you consider presenting to the Council?
Who is eligible?
How can you apply to present?
When is the deadline?
What happens during Council sessions?
What kinds of technologies have been presented?
How can you find out more?

The Interagency Council on Biomedical Imaging in Oncology brings together
representatives of the Federal Government and technology developers to expedite
the process of bringing new products to market.
Government officials on the Council represent three Department of Health and
Human Services agencies:
- National Cancer Institute (NCI)
- Food and Drug Administration (FDA)
- Centers for Medicare and Medicaid Services (CMS)
Success in bringing a new biomedical imaging technology to market hinges on the
following:
- Evidence of improved clinical outcomes
- FDA approval
- Benefit and coverage decisions by Medicare
The Council's representatives from NCI, FDA, and CMS can help you prepare to
meet these criteria for success. You will receive advice from a multi-agency
perspective on the spectrum of scientific, regulatory, and reimbursement issues
related to developing your imaging device or technology. Presenting to the
Council is…
* Presenters are responsible for any travel costs they may incur.
Any business or any academic investigator developing a device or technology
relevant to biomedical imaging in cancer may submit a request to present. Small
businesses are encouraged to apply.
Simply fill out the one page Request to Present form (
Word format, PDF
format) and fax to Paula Jacobs at 301-480-3507 or submit the necessary
information in an email to jacobsp@mail.nih.gov.
You will receive an acknowledgment of receipt in approximately one week.
Within 30 days, the Council will let you know about acceptance of your request.
Note: PDF documents can be viewed by anyone with Adobe Acrobat Reader. Download
the free
Adobe Acrobat Reader
Requests are due on February 9th for the next Council meeting on March 9th, 2010, from 8:30 AM to 12:30 PM and on September 19th for the following meeting on October 19th, 2010. The 2011 meetings are scheduled for March 8, 2011, and October 18, 2011, with requests due 1 month in advance.
A presenter typically meets with the Council for approximately an hour for an
informal discussion. The focus is on answering the presenters' questions. The
proceedings are confidential. At the end of the session, the Council summarizes
the main issues and recommends a potential action plan. The Council will send a
written summary of the session within a month.
Technologies presented in the past have included:
-
Computed tomography (CT) and combination instrumentation
-
Magnetic resonance imaging (MRI)/magnetic resonance spectroscopy (MRS)- various
instrument strengths from 1.5 Tesla to 12 Tesla.
-
Ultrasound
-
Optical imaging
-
Nuclear medicine both single photon and positron emission tomography (PET)
-
Molecular imaging agents
-
Image guided therapy
-
FDA approval pathways
-
CMS approval and funding
For further information, please contact:
Paula Jacobs, Ph.D.
Council Coordinator
Office of the Associate Director
Cancer Imaging Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
301-435-9181 tel
301-480-3507 fax
jacobsp@mail.nih.gov
|